 |
|
Placebo-Associated Blood Pressure Response and Adverse Effects in the Treatment of Hypertension
Observations From a Department of Veterans Affairs Cooperative Study
Richard A. Preston, MD;
Barry J. Materson, MD, MBA;
Domenic J. Reda, MS;
David W. Williams, MS
Arch Intern Med. 2000;160:1449-1454.
Background The use of placebo in clinical trials has been vigorously debated. Placebo control may be useful in disease states, such as stage 1 and stage 2 hypertension as defined by the Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI), in which response rates for placebo are high or close to response rates for effective therapies, or when established interventions have significant adverse effects.
Objective To compare rates for the control of blood pressure and adverse effects of placebo vs active treatment in patients with stage 1 and stage 2 hypertension.
Methods This study is a randomized controlled trial evaluating the blood pressure response and adverse effects of placebo vs 6 active treatments administered in 15 Veterans Affairs hypertension centers. The 1292 subjects of the Veterans Affairs Cooperative Study receiving single-drug therapy for hypertension were randomly allocated to receive treatment with 1 of 6 active drugs (n=1105) or placebo (n=187). Treatment success was defined as maintaining a diastolic blood pressure of less than 95 mm Hg for at least 1 year. We compared treatment success rates for the control of blood pressure and adverse effects of placebo vs active treatment. Using the Kaplan-Meier method, we also compared rates of discontinuation from placebo vs active drug treatment over time as a result of adverse drug effects and blood pressure exceeding safety limits.
Results At the end of the titration phase, 58 patients who were treated with placebo (31%) achieved a goal diastolic blood pressure lower than 90 mm Hg and 57 (30%) achieved success at 1 year. Older white patients who received placebo had a success rate of 38% vs 23% to 27% for the other age-race subgroups. The rates of discontinuation as a result of adverse drug effects were 13% for patients receiving placebo vs 12% for patients receiving active treatment (P=.40). The rates of discontinuation for blood pressure being too high were 14% for patients receiving placebo vs 7% for patients receiving active treatment (P=.01).
Conclusions Placebo control provides an important benchmark for both efficacy and adverse effects. It continues to have an appropriate place in certain therapeutic trials, particularly those involving the treatment of stage 1 and stage 2 hypertension.
From the Division of Clinical Pharmacology (Dr Preston) and Department of Medicine (Dr Materson), University of Miami School of Medicine, Miami, Fla, and Cooperative Studies Program, Edward Hines Jr Veterans Affairs Hospital, Hines, Ill (Messrs Reda and Williams).
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(10):1543.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Safety of Placebo Controls in Pediatric Hypertension Trials
Smith et al.
Hypertension 2008;51:829-833.
ABSTRACT
| FULL TEXT
RE: LETTER TO THE EDITOR ON "BIAS IN CLINICAL INTERVENTION RESEARCH"
Marmor et al.
Am J Epidemiol 2008;167:500-501.
FULL TEXT
Aspirin, Chance, and Results in Relation to Blood Pressure * Response: Aspirin Administered at Bedtime as Opposed to Upon Wakening Has an Effect on Ambulatory Blood Pressure: Further Evidence
Lopez-Rodriguez et al.
Hypertension 2004;43:e22-e23.
FULL TEXT
Ethics of Placebo Use in Pediatric Clinical Trials: The Case of Antihypertensive Drug Studies
Flynn
Hypertension 2003;42:865-869.
ABSTRACT
| FULL TEXT
The Placebo Effect in Alternative Medicine: Can the Performance of a Healing Ritual Have Clinical Significance?
Kaptchuk
ANN INTERN MED 2002;136:817-825.
ABSTRACT
| FULL TEXT
Nonspecific Medication Side Effects and the Nocebo Phenomenon
Barsky et al.
JAMA 2002;287:622-627.
ABSTRACT
| FULL TEXT
Associations Between Birth Weight and Antihypertensive Medication in Black and White Medicaid Recipients
Lackland et al.
Hypertension 2002;39:179-183.
ABSTRACT
| FULL TEXT
Antihypertensive treatment and compliance
Parienti et al.
BMJ 2001;323:1129-1129.
FULL TEXT
Placebo-Controlled Trials Are Unethical in Clinical Hypertension Research
Halpern et al.
Arch Intern Med 2000;160:3167-3169.
FULL TEXT
Other articles noted
Evid. Based Nurs. 2000;3:106-112.
FULL TEXT
|
